Logo image of INSM

INSMED INC (INSM) Stock Price, Quote, News and Overview

NASDAQ:INSM - Nasdaq - US4576693075 - Common Stock - Currency: USD

75.97  -5.58 (-6.84%)

INSM Quote, Performance and Key Statistics

INSMED INC

NASDAQ:INSM (3/3/2025, 3:53:07 PM)

75.97

-5.58 (-6.84%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High84.91
52 Week Low21.92
Market Cap13.59B
Shares178.90M
Float176.59M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-07 2025-05-07
IPO02-15 1991-02-15


INSM short term performance overview.The bars show the price performance of INSM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 2 4 6 8

INSM long term performance overview.The bars show the price performance of INSM in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of INSM is 75.97 USD. In the past month the price increased by 6.89%. In the past year, price increased by 190.63%.

INSMED INC / INSM Daily stock chart

INSM Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.88 373.43B
AMGN AMGEN INC 15.62 166.25B
GILD GILEAD SCIENCES INC 25.1 144.20B
VRTX VERTEX PHARMACEUTICALS INC 1667.79 124.25B
REGN REGENERON PHARMACEUTICALS 15.03 75.00B
ARGX ARGENX SE - ADR 242.06 37.95B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 31.26B
BNTX BIONTECH SE-ADR N/A 26.72B
ONC BEIGENE LTD-ADR N/A 26.14B
BIIB BIOGEN INC 8.63 20.72B
NTRA NATERA INC N/A 18.82B
GMAB GENMAB A/S -SP ADR 24.62 14.54B

About INSM

Company Profile

INSM logo image Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 912 full-time employees. The firm's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Company Info

INSMED INC

700 Us Highway 202/206

Bridgewater NEW JERSEY 08807 US

CEO: William H. Lewis

Employees: 912

Company Website: https://insmed.com/

Investor Relations: https://investor.insmed.com/index

Phone: 19089779900

INSMED INC / INSM FAQ

What is the stock price of INSMED INC today?

The current stock price of INSM is 75.97 USD. The price decreased by -6.84% in the last trading session.


What is the ticker symbol for INSMED INC stock?

The exchange symbol of INSMED INC is INSM and it is listed on the Nasdaq exchange.


On which exchange is INSM stock listed?

INSM stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INSMED INC stock?

23 analysts have analysed INSM and the average price target is 92.77 USD. This implies a price increase of 22.11% is expected in the next year compared to the current price of 75.97. Check the INSMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INSMED INC worth?

INSMED INC (INSM) has a market capitalization of 13.59B USD. This makes INSM a Large Cap stock.


How many employees does INSMED INC have?

INSMED INC (INSM) currently has 912 employees.


What are the support and resistance levels for INSMED INC (INSM) stock?

INSMED INC (INSM) has a support level at 80.54. Check the full technical report for a detailed analysis of INSM support and resistance levels.


Is INSMED INC (INSM) expected to grow?

The Revenue of INSMED INC (INSM) is expected to grow by 37.17% in the next year. Check the estimates tab for more information on the INSM EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INSMED INC (INSM) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INSMED INC (INSM) stock pay dividends?

INSM does not pay a dividend.


When does INSMED INC (INSM) report earnings?

INSMED INC (INSM) will report earnings on 2025-05-07.


What is the Price/Earnings (PE) ratio of INSMED INC (INSM)?

INSMED INC (INSM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.58).


What is the Short Interest ratio of INSMED INC (INSM) stock?

The outstanding short interest for INSMED INC (INSM) is 8.23% of its float. Check the ownership tab for more information on the INSM short interest.


INSM Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to INSM. When comparing the yearly performance of all stocks, INSM is one of the better performing stocks in the market, outperforming 98.01% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

INSM Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to INSM. Both the profitability and financial health of INSM have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

INSM Financial Highlights

Over the last trailing twelve months INSM reported a non-GAAP Earnings per Share(EPS) of -5.58. The EPS decreased by -4.59% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -45.12%
ROE -320.2%
Debt/Equity 3.95
Chartmill High Growth Momentum
EPS Q2Q%-2.73%
Sales Q2Q%24.79%
EPS 1Y (TTM)-4.59%
Revenue 1Y (TTM)19.17%

INSM Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to INSM. The Buy consensus is the average rating of analysts ratings from 23 analysts.

For the next year, analysts expect an EPS growth of 16.18% and a revenue growth 37.17% for INSM


Ownership
Inst Owners112.91%
Ins Owners1.06%
Short Float %8.23%
Short Ratio7.91
Analysts
Analysts85.22
Price Target92.77 (22.11%)
EPS Next Y16.18%
Revenue Next Year37.17%